Cell and gene therapy companies have been rapidly populating over the past few years, making the cell therapy market a high-value, fast-growth market. Key drivers for the market include high rates of cell therapy clinical trials, accelerated pathways for cell therapy product approvals, new technologies to support cell therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
The market gained additional momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta).
These historic events demonstrate to investors, the public and funding providers alike that the cell and gene therapy is a market that has emerged, no longer one that is evolving in the future.
With accelerating momentum fueling the industry, BioInformant honored to announce that we are a sponsor for Phacilitate’s Cell and Gene Therapy World in Miami, Florida on January 22-25, 2018. [Read more…]